Related Experiment Video
Updated: Nov 1, 2025
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.3K
Ticagrelor Use in Stroke Patients: Past, Present, and Future
Rahul Chandra1, Harneel Saini1, Russell Cerejo1
1Department of Neurology, Allegheny Health Network, Pittsburgh, PA, USA.
Vascular Health and Risk Management
|June 24, 2021
Summary
Ticagrelor shows promise for secondary stroke prevention, offering an alternative to traditional antiplatelet drugs like aspirin. This review compares its efficacy and safety in ischemic stroke patients.
Area of Science:
- Neurology
- Pharmacology
- Cardiology
Background:
- Antiplatelet medications are crucial for secondary stroke prevention.
- Commonly used agents include aspirin, clopidogrel, and aspirin-dipyridamole.
- Ticagrelor and prasugrel are increasingly considered for stroke prevention.
Purpose of the Study:
- To review the pharmacology of ticagrelor.
- To examine existing literature on ticagrelor in cardiology and stroke trials.
- To compare ticagrelor's efficacy, limitations, and side effects with other antiplatelet drugs for secondary stroke prevention.
Main Methods:
- Literature review of pharmacology, cardiology trials, and stroke studies.
- Comparative analysis of antiplatelet medications.
Main Results:
- Ticagrelor has demonstrated potential in recent studies for secondary stroke prevention.
- Efficacy, limitations, and side effects vary among different antiplatelet agents.
Conclusions:
- Ticagrelor represents a potential new option for secondary stroke prevention.
- Further research is needed to fully establish its role compared to existing therapies.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
791
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
791
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
01:29Venous Thrombosis III: Interprofessional Care
82
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
82
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
102
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
102
01:30Acute Coronary Syndrome I: Introduction
201
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
201
01:17Ischemic Heart Disease: Overview
2.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.2K